JP2022513099A5 - - Google Patents
Info
- Publication number
- JP2022513099A5 JP2022513099A5 JP2021527926A JP2021527926A JP2022513099A5 JP 2022513099 A5 JP2022513099 A5 JP 2022513099A5 JP 2021527926 A JP2021527926 A JP 2021527926A JP 2021527926 A JP2021527926 A JP 2021527926A JP 2022513099 A5 JP2022513099 A5 JP 2022513099A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- tnf
- vector
- cells
- mutant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862769405P | 2018-11-19 | 2018-11-19 | |
| US62/769,405 | 2018-11-19 | ||
| US201862773372P | 2018-11-30 | 2018-11-30 | |
| US62/773,372 | 2018-11-30 | ||
| US201962791464P | 2019-01-11 | 2019-01-11 | |
| US62/791,464 | 2019-01-11 | ||
| PCT/US2019/062009 WO2020106619A1 (en) | 2018-11-19 | 2019-11-18 | Suicide gene |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022513099A JP2022513099A (ja) | 2022-02-07 |
| JP2022513099A5 true JP2022513099A5 (cg-RX-API-DMAC7.html) | 2022-11-21 |
Family
ID=68848450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021527926A Pending JP2022513099A (ja) | 2018-11-19 | 2019-11-18 | 自殺遺伝子 |
Country Status (18)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7773789B2 (ja) | 2020-03-28 | 2025-11-20 | ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム | 癌の治療のための細胞免疫療法 |
| AU2022372894A1 (en) | 2021-10-20 | 2024-04-18 | Takeda Pharmaceutical Company Limited | Compositions targeting bcma and methods of use thereof |
| WO2023177954A1 (en) * | 2022-03-18 | 2023-09-21 | University Of Rochester | Combination therapy for treatment of cancer, methods and systems of delivery thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3817955A1 (de) | 1988-05-27 | 1989-11-30 | Hoechst Ag | Tnf-inhibitor enthaltendes arzneimittel |
| US6143866A (en) | 1989-07-18 | 2000-11-07 | Amgen, Inc. | Tumor necrosis factor (TNF) inhibitor and method for obtaining the same |
| WO1994000555A2 (en) * | 1992-06-25 | 1994-01-06 | Cetus Oncology Corporation | Compositions for the inhibition of protein hormone formation and uses thereof |
| US20040121971A1 (en) * | 2002-12-20 | 2004-06-24 | Gang Chen | Therapeutic use of tumor necrosis factor-alpha mutein |
| JPWO2005035586A1 (ja) * | 2003-10-08 | 2007-11-22 | 協和醗酵工業株式会社 | 融合蛋白質組成物 |
| AU2011258425B2 (en) * | 2010-05-27 | 2015-12-10 | Merck Sharp & Dohme Llc | Method for preparing antibodies having improved properties |
| US20130071414A1 (en) * | 2011-04-27 | 2013-03-21 | Gianpietro Dotti | Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies |
| WO2015188141A2 (en) * | 2014-06-06 | 2015-12-10 | Memorial Sloan-Kettering Cancer Ceneter | Mesothelin-targeted chimeric antigen receptors and uses thereof |
| CA2962251A1 (en) * | 2014-10-03 | 2016-04-07 | Ntercept, Llc | Compositions and methods for inhibiting the biological activity of soluble biomolecules |
| MX2018001568A (es) * | 2015-08-07 | 2019-04-25 | Seattle Children´S Hospital Dba Seattle Children´S Res Institute | Celulas t biespecificas de receptor quimerico de antigeno (car) para focalizacion a tumores solidos. |
| KR20240024328A (ko) * | 2016-11-22 | 2024-02-23 | 알로플렉스 바이오테라퓨틱스 | 동종이형 종양 세포 백신 |
| CN107365798B (zh) * | 2017-07-13 | 2020-07-14 | 山东省齐鲁细胞治疗工程技术有限公司 | 一种携带iCasp9自杀基因的CD19-CAR-T细胞及其应用 |
| CN107337737B (zh) * | 2017-07-18 | 2020-02-07 | 深圳市免疫基因治疗研究院 | 一种嵌合抗原受体及其应用 |
| CN107400168B (zh) * | 2017-07-18 | 2020-02-07 | 深圳市免疫基因治疗研究院 | 一种基于cd117的嵌合抗原受体及其应用 |
| CN107312098B (zh) * | 2017-07-18 | 2020-06-12 | 深圳市免疫基因治疗研究院 | 一种基于cd22的嵌合抗原受体及其应用 |
| CN107312097B (zh) * | 2017-07-18 | 2020-06-16 | 深圳市免疫基因治疗研究院 | 一种基于cd30的嵌合抗原受体及其应用 |
| CN107245106B (zh) * | 2017-07-18 | 2020-06-12 | 深圳市免疫基因治疗研究院 | 一种基于cd10的嵌合抗原受体及其应用 |
| CN107245107B (zh) * | 2017-07-18 | 2020-02-07 | 深圳市免疫基因治疗研究院 | 一种基于cd20的嵌合抗原受体及其应用 |
-
2019
- 2019-11-18 CN CN201980086243.2A patent/CN113272320A/zh active Pending
- 2019-11-18 EP EP19818397.2A patent/EP3883959A1/en not_active Withdrawn
- 2019-11-18 CA CA3120349A patent/CA3120349A1/en active Pending
- 2019-11-18 JP JP2021527926A patent/JP2022513099A/ja active Pending
- 2019-11-18 SG SG11202105238YA patent/SG11202105238YA/en unknown
- 2019-11-18 PE PE2021000739A patent/PE20211236A1/es unknown
- 2019-11-18 WO PCT/US2019/062009 patent/WO2020106619A1/en not_active Ceased
- 2019-11-18 BR BR112021009634-5A patent/BR112021009634A2/pt not_active IP Right Cessation
- 2019-11-18 KR KR1020217018726A patent/KR20210093977A/ko not_active Ceased
- 2019-11-18 AU AU2019384115A patent/AU2019384115A1/en not_active Abandoned
- 2019-11-18 MX MX2021005847A patent/MX2021005847A/es unknown
- 2019-11-18 US US17/309,315 patent/US20220023343A1/en not_active Abandoned
- 2019-11-19 TW TW108141960A patent/TW202039538A/zh unknown
-
2021
- 2021-05-18 CL CL2021001300A patent/CL2021001300A1/es unknown
- 2021-05-18 IL IL283242A patent/IL283242A/en unknown
- 2021-05-19 PH PH12021551142A patent/PH12021551142A1/en unknown
- 2021-06-15 CO CONC2021/0007824A patent/CO2021007824A2/es unknown
- 2021-06-18 EC ECSENADI202144662A patent/ECSP21044662A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11802143B2 (en) | Therapeutic agents | |
| JP7198670B2 (ja) | 免疫調整性il2r融合タンパク質およびその使用 | |
| Redeker et al. | Improving adoptive T cell therapy: the particular role of T cell costimulation, cytokines, and post-transfer vaccination | |
| CN103483452B (zh) | 双信号独立的嵌合抗原受体及其用途 | |
| US12577287B2 (en) | T cell receptors and methods of use thereof | |
| JP7566628B2 (ja) | キメラ抗原受容体を発現する免疫細胞 | |
| JP2022512958A (ja) | トランス共刺激分子と組み合わされた抗gpc3キメラ抗原受容体(car)及びその治療的用途 | |
| JP2019525898A (ja) | ヒト白血球抗原拘束ガンマデルタt細胞受容体及びその使用方法 | |
| JP7825752B2 (ja) | T細胞受容体及びその使用方法 | |
| JP2016519068A5 (cg-RX-API-DMAC7.html) | ||
| JP2018501786A5 (cg-RX-API-DMAC7.html) | ||
| JP2016521709A5 (cg-RX-API-DMAC7.html) | ||
| KR20180057723A (ko) | 항-cd30 키메라성 항원 수용체 | |
| JP2021525534A5 (cg-RX-API-DMAC7.html) | ||
| JP2019512251A (ja) | Pd−1及び4−1bbの融合タンパク質 | |
| CN112055717A (zh) | 用在免疫细胞中表达的膜结合抗细胞因子非信号传导粘合剂中和人细胞因子 | |
| JP7727547B2 (ja) | T細胞受容体及びその使用方法 | |
| KR20210149048A (ko) | T 세포 수용체 및 이의 사용 방법 | |
| CN112533629A (zh) | 结合使用il-10药剂与嵌合抗原受体细胞疗法的组合物和方法 | |
| AU2018378955A1 (en) | Methods for enhancing and maintaining CAR-T cell efficacy | |
| KR20220087431A (ko) | T 세포 수용체 및 이의 사용 방법 | |
| TWI881993B (zh) | T細胞受體及其使用方法 | |
| TWI869426B (zh) | T細胞受體及其使用方法 | |
| TW202039538A (zh) | 自殺基因 | |
| JP2025522815A (ja) | キメラ細胞内シグナル伝達ドメインに連結されたbcmaナノボディを含むキメラ抗原受容体 |